36 R. J. Kreitman et al.
properties of the novel ribosyl-amino acid and its hydrolysis 35. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I
products. J Biol Chem 1980;255:10717–10720. trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22)
17. Hwang J, FitzGerald DJ, Adhya S, et al. Functional domains in patients with B-cell malignancies. J Clin Oncol 2005;
of Pseudomonas exotoxin identified by deletion analysis of the 23:6719–6729.
gene expressed in E. coli. Cell 1987;48:129–136. 36. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II
18. Allured VS, Collier RJ, Carroll SF, et al. Structure of exotoxin trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22)
AofPseudomonas aeruginosa at 3.0 Angstrom resolution. Proc in patients with hairy cell leukemia. J Clin Oncol 2009;27:
Natl Acad Sci USA 1986;83:1320–1324. 2983.
19. Pastan I, Hassan R, FitzGerald DJP, et al. Immunotoxin 37. Salvatore G, Beers R, Margulies I, et al. Improved Cytotoxic
therapy of cancer. Nat Rev Cancer 2006;6:559–565. activity towards cell lines and fresh leukemia cells of a mutant
20. Williams DP, Snider CE, Strom TB, et al. Structure/function anti-CD22 immunotoxin obtained by antibody phage display.
analysis of interleukin-2-toxin (DAB
486
-IL-2). Fragment B Clin Cancer Res 2002;8:995–1002.
sequences required for the delivery of fragment A to the cytosol 38. Decker T, Oelsner M, Kreitman RJ, et al. Induction of
of target cells. J Biol Chem 1990;265:11885–11889. caspase-dependent programmed cell death in b-cell chronic
21. Olsen E, Duvic M, Frankel A, et al. Pivotal Phase III Trial of lymphocytic leukemia cells by anti-CD22 immunotoxins.
Two Dose Levels of Denileukin Diftitox for the Treatment of Blood 2004;103:2718–2726.
Cutaneous T-Cell Lymphoma. J Clin Oncol 2001;19:376– 39. Ho M, Kreitman RJ, Onda M, et al. In vitro antibody
388. evolution targeting germline hot spots to increase activity
22. Foss F. Clinical Experience With Denileukin Diftitox (ON- of an anti-CD22 immunotoxin. J Biol Chem 2005;280:607–
TAK). Semin Oncol 2006;33:11–16. 617.
23. Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein 40. Tallman MS, Zakarija A. Hairy cell leukemia: survival and
engineering of antibody binding sites: recovery of specific relapse. Long-term follow-up of purine analog-based therapy
activity in an antidigoxin single-chain Fv analogue produced and approach for relapsed disease. Transfus Apher Sci 2005;
in Escherichia coli. Proc Natl Acad Sci USA 1988;85:5879– 32:99–103.
5883. 41. Robak T. Current treatment options in hairy cell leukemia and
24. Chaudhary VK, Queen C, Junghans RP, et al. A recombinant hairy cell leukemia variant. Cancer Treat Rev 2006;32:365–
immunotoxin consisting of two antibody variable domains 376.
fused to Pseudomonas exotoxin. Nature 1989;339:394–397. 42. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy
25. Mansfield E, Amlot P, Pastan I, et al. Recombinant RFB4 cell leukemia with 2-chlorodeoxyadenosine via the Group C
immunotoxins exhibit potent cytotoxic activity for CD22- protocol mechanism of the National Cancer Institute: a report
bearing cells and tumors. Blood 1997;90:2020–2026. of 979 patients. J Clin Oncol 1998;16: 3007–3015.
26. Kreitman RJ, Wang QC, FitzGerald DJP, et al. Complete 43. Lauria F, Bocchia M, Marotta G, et al. Weekly administration
regression of human B-cell lymphoma xenografts in mice of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia
treated with recombinant anti-CD22 immunotoxin is effective and reduces infectious complications. Haematolo-
RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus mon- gica 1999;84:22–25.
keys. Int J Cancer 1999;81:148–155. 44. Robak T, Blasinska-Morawiec M, Blonski J, et al. 2-
27. Kreitman RJ, Margulies I, Stetler-Stevenson M, et al. chlorodeoxyadenosine (cladribine) in the treatment of hairy
Cytotoxic activity of disulfide-stabilized recombinant immu- cell leukemia and hairy cell leukemia variant: 7-year experi-
notoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant ence in Poland. Eur J Haematol 1999;62:49–56.
cells from patients with B-cell leukemias. Clin Cancer Res 45. Grever M, Kopecky K, Foucar MK, et al. Randomized
2000;6:1476–1487. comparison of pentostatin versus interferon alfa-2a in pre-
28. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in viously untreated patients with hairy cell leukemia: an
refractory hairy cell leukemia to a recombinant immunotoxin. intergroup study. J Clin Oncol 1995;13:974–982.
Blood 1999;94:3340–3348. 46. Grever MR. Pentostatin: Impact on outcome in hairy cell
29. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of leukemia. Hematol Oncol Clin N Am 2006;20:1099–1108.
recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in 47. Maloisel F, Benboubker L, Gardembas M, et al. Long-term
patients with hematologic malignancies. J Clin Oncol outcome with pentostatin treatment in hairy cell leukemia
2000;18:1614–1636. patients. A French retrospective study of 238 patients.
30. Kreitman RJ, Chaudhary VK, Kozak RW, et al. Recombinant Leukemia 2003;17:45–51.
toxins containing the variable domains of the anti-Tac 48. Johnston JB, Eisenhauer E, Wainman N, et al. Long-term
monoclonal antibody to the interleukin-2 receptor kill outcome following treatment of hairy cell leukemia with
malignant cells from patients with chronic lymphocytic pentostatin (Nipent): a National Cancer Institute of Canada
leukemia. Blood 1992;80:2344–2352. Study. Semin Oncol 2000;27:32–36.
31. Kreitman RJ, Batra JK, Seetharam S, et al. Single-chain 49. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-
immunotoxin fusions between anti-Tac and Pseudomonas up of remission duration, mortality, and second malignancies
exotoxin: relative importance of the two toxin disulfide bonds. in hairy cell leukemia patients treated with pentostatin. Blood
Bioconjug Chem 1993;4:112–120. 2000;96:2981–2986.
32. Matutes E, Wotherspoon A, Catovsky D. The variant form of 50. Ribeiro P, Bouaffia F, Peaud PY, et al. Long term outcome of
hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; patients with hairy cell leukemia treated with pentostatin.
16:41–56. Cancer 1999;85:65–71.
33. Matutes E. Immunophenotyping and differential diagnosis of 51. Matutes E, Meeus P, McLennan K, et al. The significance of
hairy cell leukemia. Hematol Oncol Clin N Am 2006;20: minimal residual disease in hairy cell leukaemia treated with
1051–1063. deoxycoformycin: a long-term follow-up study. Br J Haematol
34. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the 1997;98:375–383.
Anti-CD22 Recombinant Immunotoxin BL22 in Chemother- 52. Cassileth PA, Cheuvart B, Spiers AS, et al. Pentostatin
apy-Resistant Hairy-Cell Leukemia. N Engl J Med 2001; induces durable remissions in hairy cell leukemia. J Clin Oncol
345:241–247. 1991;9:243–246.
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46